MONTREAL, QUEBEC--(Marketwire - October 02, 2008) - MethylGene Inc. (TSX: MYG) today announced that Health Canada has approved the Company's clinical trial application (CTA) for MGCD290, a fungal Hos2 histone deacetylase (HDAC) inhibitor to be used in combination with azoles for the treatment of fungal infections.
